Expertise and resources to facilitate
Read or watch to learn more
Preclinical characterization of oncology nanomedicines
Expediting nanomedicine development
Protocols

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Nanotechnology Characterization Lab

Eliminating suffering and death from cancer requires an unprecedented collaborative effort that leverages resources from government, industry, and academia. Working in concert with the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI) established the Nanotechnology Characterization Laboratory to perform preclinical efficacy and toxicity testing of nanoparticles.

The NCL serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical infrastructure and characterization services to nanomaterial providers, the NCL accelerates the transition of basic nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer.

There are multiple ways the NCL can help nanotech researchers and developers advance their technology, including characterization, reformulation, optimization, lead selection, method development, and more.

Learn about how to collaborate with the NCL.

News & Updates

UPDATE--The online Immunology Workshop originally planned for June 8-12 and 15-18, 2020 has been reschdeuled to May 18-22, 25-28, 2020.

The NCL is collecting feedback....Please take this brief survey so that we can stay at the forefront of your nanotechnology needs.

The NCL recently completed a 2.5 year interagency collaboration with the US Food and Drug Administration (FDA) to evaluate the bioequivalence of marketed nanomedicines.

Meet Us @

UPDATE--The BIO International Convention originally planned for June 8-11, 2020 has been converted to a virtual meeting due to the rapidly evolving COVID-19...

UPDATE--TheTech Connect World Innovation Conference & Expo originally planned for June 29-July 1, 2020 has been postponed due to the rapidly evolving COVID...

UPDATE--The CLINAM meeting originally planned for May 17-20, 2020 has been rescheduled due to the rapidly evolving COVID-19 situation.